Approved and emerging treatments of malignant pleural mesothelioma in elderly patients

Giovanni Luca Ceresoli, Antonio Rossi

Research output: Contribution to journalReview articlepeer-review


Introduction: Malignant pleural mesothelioma (MPM) is a rare neoplasm with asbestos exposure as the dominant etiologic agent. Owing to the long latent period following exposure, MPM is often diagnosed late in life. Despite this, elderly patients are under-represented in clinical trials. To date, data regarding the tolerability and efficacy of anticancer treatments for elderly patients affected by MPM are still lacking. Areas covered: The current state-of-the-art of approved treatments employed in the treatment of MPM elderly patients is reviewed and discussed, with a look to emerging therapies. A structured search of bibliographic databases for peer-reviewed research literature and of main meeting abstracts using a focused review question was undertaken. Expert opinion: Even though the median age of MPM patients enrolled in the most recent experimental trials is increasing, no specific analysis has been reported so far in the elderly. Moreover, no data are available for the ‘oldest of the elderly’ (>75 years). Treatment of elderly patients with MPM is one of the major challenges to the clinician. There is a clear need of large, well-conducted retrospective studies and above all of prospective investigations in this patient population, both in the first-and in the second-line setting.

Original languageEnglish
JournalExpert Review of Respiratory Medicine
Publication statusAccepted/In press - Jan 1 2019


  • elderly
  • malignant pleural mesothelioma
  • multimodality treatments

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Approved and emerging treatments of malignant pleural mesothelioma in elderly patients'. Together they form a unique fingerprint.

Cite this